Brief: Anebulo Pharmaceuticals Says On Track To Commence Phase 2 Proof-Of-Concept Clinical Trial With Aneb-001 In Q4

Anebulo Pharmaceuticals

21/06/2021 21:13

June 21 (Reuters) - Anebulo Pharmaceuticals Inc  ANEB.O :
    * ANEBULO PHARMACEUTICALS REPORTS RECENT BUSINESS HIGHLIGHTS
AND
ANNOUNCES THIRD QUARTER FISCAL YEAR 2021 FINANCIAL RESULTS
    * ANEBULO PHARMACEUTICALS INC - REMAINS ON TRACK TO COMMENCE
PHASE
2 PROOF-OF-CONCEPT CLINICAL TRIAL WITH ANEB-001 IN Q4 OF 2021
    * ANEBULO PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS
WERE
$3.3 MILLION AS OF MARCH 31, 2021
    * ANEBULO PHARMACEUTICALS - IPO NET PROCEEDS PROVIDE
ADEQUATE
FUNDING FOR CO'S PLANNED BUSINESS OPERATIONS AND CLINICAL
STUDIES THROUGH DEC 31, 2022
    * ANEBULO PHARMACEUTICALS INC - ANTICIPATES TOPLINE RESULTS
FROM
PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL WITH ANEB-001 IN FIRST
HALF OF 2022

Source text for Eikon:  ID:nBw2WnThJa 
Further company coverage:  ANEB.O 

 ((Reuters.Briefs@thomsonreuters.com;))